HUE035393T2 - Procedures and preparations for the treatment of HIV-related diarrhea - Google Patents

Procedures and preparations for the treatment of HIV-related diarrhea Download PDF

Info

Publication number
HUE035393T2
HUE035393T2 HUE11837249A HUE11837249A HUE035393T2 HU E035393 T2 HUE035393 T2 HU E035393T2 HU E11837249 A HUE11837249 A HU E11837249A HU E11837249 A HUE11837249 A HU E11837249A HU E035393 T2 HUE035393 T2 HU E035393T2
Authority
HU
Hungary
Prior art keywords
crofelemer
patient
diarrhea
daily
day
Prior art date
Application number
HUE11837249A
Other languages
English (en)
Hungarian (hu)
Inventor
William Forbes
Enoch Bortey
Steven King
Pravin Chaturvedi
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035393(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of HUE035393T2 publication Critical patent/HUE035393T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HUE11837249A 2010-10-31 2011-10-31 Procedures and preparations for the treatment of HIV-related diarrhea HUE035393T2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US40933510P 2010-11-02 2010-11-02
US41624910P 2010-11-22 2010-11-22
US201161434379P 2011-01-19 2011-01-19

Publications (1)

Publication Number Publication Date
HUE035393T2 true HUE035393T2 (en) 2018-05-02

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11837249A HUE035393T2 (en) 2010-10-31 2011-10-31 Procedures and preparations for the treatment of HIV-related diarrhea

Country Status (20)

Country Link
US (4) US8962680B2 (enExample)
EP (1) EP2632550B1 (enExample)
JP (2) JP6063385B2 (enExample)
CN (2) CN103370101A (enExample)
AU (1) AU2011320155B2 (enExample)
BR (1) BR112013010774A2 (enExample)
CA (1) CA2816416C (enExample)
DK (1) DK2632550T3 (enExample)
EC (1) ECSP13012650A (enExample)
ES (1) ES2635435T3 (enExample)
HK (1) HK1249036A1 (enExample)
HU (1) HUE035393T2 (enExample)
MX (1) MX348184B (enExample)
PE (1) PE20140036A1 (enExample)
PH (1) PH12013500857A1 (enExample)
PL (1) PL2632550T3 (enExample)
PT (1) PT2632550T (enExample)
RU (1) RU2597746C2 (enExample)
WO (1) WO2012058664A1 (enExample)
ZA (1) ZA201303136B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク. 便秘型過敏性腸症候群の治療方法
US8852649B2 (en) 2006-05-01 2014-10-07 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
BR112013010774A2 (pt) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
US20140163096A1 (en) * 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
JP2023538186A (ja) * 2020-06-19 2023-09-07 ナポ ファーマシューティカルズ インク. 化学療法誘発性下痢を治療するための方法及び組成物
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
EP0935417B1 (en) * 1996-10-16 2009-05-06 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
US20080025966A1 (en) * 2004-01-30 2008-01-31 Currie Mark G Methods And Compositions For The Treatment Of Gastrointestinal disorders
CA2667449A1 (en) * 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
JP2009524585A (ja) 2005-12-15 2009-07-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク. 便秘型過敏性腸症候群の治療方法
US8852649B2 (en) 2006-05-01 2014-10-07 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2010021681A2 (en) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EA023814B1 (ru) 2009-08-26 2016-07-29 Гленмарк Фармасьютикалс Лтд. Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
BR112013010774A2 (pt) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
BR112013018688B1 (pt) 2011-01-27 2021-08-24 Napo Pharmaceuticals, Inc Método de produção de uma composição polimérica de proantocianidina
RU2014124981A (ru) 2011-12-22 2016-02-10 Гленмарк Фармасьютикалс Лимитед Неэнтеросолюбильная фармацевтическая композиция, содержащая крофелемер
US20140163096A1 (en) 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea

Also Published As

Publication number Publication date
JP6310971B2 (ja) 2018-04-11
CA2816416C (en) 2020-02-11
AU2011320155A1 (en) 2013-05-09
RU2597746C2 (ru) 2016-09-20
MX348184B (es) 2017-06-02
CN103370101A (zh) 2013-10-23
BR112013010774A2 (pt) 2017-03-21
JP2017019806A (ja) 2017-01-26
ZA201303136B (en) 2016-01-27
EP2632550B1 (en) 2017-05-03
PE20140036A1 (es) 2014-01-31
CN107595836A (zh) 2018-01-19
PL2632550T3 (pl) 2017-10-31
PH12013500857A1 (en) 2018-01-17
US20120107370A1 (en) 2012-05-03
US9585868B2 (en) 2017-03-07
CA2816416A1 (en) 2012-05-03
AU2011320155B2 (en) 2016-02-25
WO2012058664A1 (en) 2012-05-03
US20120184605A1 (en) 2012-07-19
US8962680B2 (en) 2015-02-24
EP2632550A4 (en) 2014-04-23
MX2013004873A (es) 2013-08-21
PT2632550T (pt) 2017-08-02
EP2632550A1 (en) 2013-09-04
US20150190367A1 (en) 2015-07-09
ES2635435T3 (es) 2017-10-03
ECSP13012650A (es) 2013-10-31
DK2632550T3 (en) 2017-08-07
RU2013123794A (ru) 2014-12-10
US20140294903A1 (en) 2014-10-02
HK1249036A1 (zh) 2018-10-26
JP2013540826A (ja) 2013-11-07
JP6063385B2 (ja) 2017-01-18

Similar Documents

Publication Publication Date Title
DK2632550T3 (en) METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRIA
US20140163096A1 (en) Methods and compositions for treating hiv-associated diarrhea
AU2018275685B2 (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
US20190247329A1 (en) Composition and method for treating neurological disease
AU2018278312B2 (en) Methods and compositions for treating congenital diarrhea disorder
HK1183263A (en) Methods and compositions for treating hiv-associated diarrhea
HK1183263B (en) Methods and compositions for treating hiv-associated diarrhea
CA3235677A1 (en) Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance
WO2022115481A1 (en) Methods and compositions for treating post-acute infection gastrointestinal disorders
D'Arcy Adverse reactions to excipients in pharmaceutical formulations
KR102248513B1 (ko) 무좀 예방 및 치료용 조성물
Marbury et al. Pharmacokinetics and safety of a single oral dose of once‐daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment
KR100768401B1 (ko) 무좀방지용 화장료 조성물
Lemar Cell death in the human pathogen Candida albicans: effects of garlic (Allium sativum), and garlic constituents allyl alcohol and diallyl disulphide
Bruce Superficial fungal infections
Huang Cutaneous effect of immunosuppressive medications
WO2018051363A1 (en) Antifungal formulations from medicinal plants for vaginal candidiasis
HK1183818A (en) Oral spray formulations and methods for administration of sildenafil citrate
HK1183818B (en) Oral spray formulations and methods for administration of sildenafil citrate